The Annual General Meeting of BioGaia AB on 6 May 2014 voted to approve the
following resolutions:
• adoption of the annual report
• discharge from liability for the Board members and the Managing Director - a
dividend of SEK 7.00 per share
• re-election of Board members Jan Annwall, Stefan Elving, David Dangoor, Inger
Holmström, Jörgen Thorball and Paula Zeilon
• Election of Communication consultant Brit Stakston and attorney Jan Litborn as
Board members
- Brit Stakston, born 1961, is a partner at JMW Communications AB and educated
at the University of Stockholm in areas such as media and communication science,
ethnology and pedagogy.
- Jan Litborn, born 1951, is a partner in Law firm Glimstedt, LL.M. Stockholm
University and economic studies at the Stockholm School of Economics. January
Litborn has wide experience of board work.
• re-election of David Dangoor as Board Chairman
• re-election of the registered Accounting firm Grant Thornton Sweden AB
• Board member compensation in an amount of SEK 300,000 to the Chairman and SEK
150,000 to each of the other Board members not employed by the company
• auditors’ fee shall be paid according to approved account
• regarding principles for remuneration and other terms of employment for senior
executives in accordance with the Board’s proposal
• regarding the Nominating Committee in accordance with the Nominating
Committee’s proposal
All decisions that were passed by the Annual General Meeting are consistent with
the Board’s and Nominating Committee’s previously published proposals.
Latest press releases from BioGaia
2014-05-06 BioGaia AB Interim Management Statement 1 January – 31 March 2014
2014-04-07 Notice to attend the Annual General Meeting of BioGaia AB
2014-03-26 Sale of shares in BioGaia AB
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 7 May 2014 8:00 am
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
